Bioeasy announced that its operating revenue in the first half of 2025 was 109 million yuan, a year-on-year increase of 5.44%. The net profit attributable to shareholders of the listed company was 2.3395 million yuan, compared to a loss of 1.5595 million yuan in the same period last year. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital